China Isotope & Radiation Corp. (HK:1763) has released an update.
China Isotope & Radiation Corporation’s subsidiary, CNNC Chengying, has achieved a milestone by obtaining a registration certificate from China’s National Medical Products Administration for its innovative Gamma-ray Stereotactic Radiotherapy System. This advanced medical equipment, powered by domestically-produced cobalt-60, promises to enhance the efficiency and precision of cancer treatments in China. The company anticipates that this achievement will support China’s ‘Healthy China 2030’ initiative and bolster national health security.
For further insights into HK:1763 stock, check out TipRanks’ Stock Analysis page.
